Molecular genetics of antithrombin deficiency

Blood Reviews

Volumn 10, Issue 2, 1996, Pages 59-74

  Lane, D A ^a   Kunz, G ^a   Olds, R J ^b   Thein, S L ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN BINDING PROTEIN;

AMINO ACID SEQUENCE; ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; BINDING SITE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CRYSTAL STRUCTURE; GENE MUTATION; GENE STRUCTURE; HIGH RISK POPULATION; HUMAN; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; X RAY CRYSTALLOGRAPHY;

EID: 0030037196     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90034-X     Document Type: Article

References (167)

1. 1 antitrypsin and antithrombin III. In: Collen D, Wiman B, Verstraete M, eds. The Physiological Inhibitors of Blood Coagulation and Fibrinolysis. Amsterdam: Elsevier Science Publishers, 1979: 43-54.
2. Prochownik EV, Markam AF, Orkin SH. Isolation of a cDNA clone for human antithrombin III. J Biol Chem 1983; 258: 8389-8394.
3. Bock SC, Wion KL, Vehar GA, Lawn RM. Cloning and expression of the cDNA for human antithrombin III. Nucl Acids Res 1982; 10: 8113-8125.
4. Chandra T, Stackhouse R, Kidd VJ, Woo SLC. Isolation and sequence characterisation of a cDNA clone of human antithrombin III. Proc Natl Acad Sci USA 1983; 80: 1845-1848.
5. Peterson CB, Blackburn MN. Isolation and characterisation of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 1985; 260: 610-615.
6. Brennan SO, George PM, Jordan RE. Physiological variant of antithrombin III lacks carbohydrate side chain at Asn 135. FEBS Lett 1987; 219: 431-436.
7. Picard V, Ersdal-Badju E, Bock SC. Partial glycosylation of antithrombin III asparagine 135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the β-antithrombin III isoform with enhanced heparin affinity. Biochemistry 1995; 34: 8433-84440.
8. Sheffield WP, Brothers AB, Wells MJ, Hatton MWC, Clarke BJ, Blajchman MA. Molecular cloning and expression of rabbit antithrombin III. Blood 1992; 79: 2330-2339.
9. Niessen RWL, Sturk A, Hordijk PL, Michiels F, Peters M. Sequence characterization of a sheep cDNA for antithrombin III. Biochim Biophys Acta 1992; 1171: 207-210.
10. Mejdoub H, Le Ret M, Boulanger Y, Maman M, Choay J, Reinbolt J. The complete amino acid sequence of bovine antithrombin (ATIII). J Prot Chem 1991; 10: 205-212.
11. Wu J, Sheffield W, Blajchman M. Molecular cloning and cell free expression of mouse antithrombin III. Thromb Haemost 1992; 68: 291-296.
12. Bjork I, Olson ST, Shore JD. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and the clotting proteinases. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. London: Edward Arnold, 1989: 229-255.
13. Bjork I, Danielsson A, Fenton JW, Jornvall H. The site in human antithrombin for functional proteolytic cleavage by human thrombin. FEBS Letts 1981; 126: 257-260.
14. Bjork I, Jackson CM, Jornvall H, Lavine KK, Nording K, Salsgiver WJ. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with Factor IXa, Factor Xa and thrombin. J Biol Chem 1982; 257: 2406-2411.
15. Rao LVM, Rapaport SI, Hoang AD. Binding of factor Vila to tissue factor permits rapid antithrombin III/heparin inhibition of factor Vila. Blood 1993; 81: 2600-2607.
16. Rao L. Nordfang O, Hoang A, Pendurthi U. Mechanism of antithrombin III inhibition of factor Vila/tissue factor activity on cell surfaces. Comparision with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-129.
17. 1-antitrypsin for the structure and function of serpins. Biochemistry 1989; 28: 8951-8966.
18. Carrell RW, Owen M, Brennan S, Vaughan L. Carboxy terminal fragment of human al-antitrypsin from hydroxlamine cleavage: homology with antithrombin III. Biochem Biophys Res Comm 1979; 91: 1032-1037.
19. 1-proteinase inhibitor. Biochem Biophys Res Commun 1980; 95: 864-871.
20. Loebermann H, Tokuoka R, Diesenhofer J, Huber R. Human alpha 1 -proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 1984; 177: 531-556.
21. Mourey L, Samama JP, Delarue M et al. Antithrombin III: structural and functional aspects. Biochimie 1990; 72: 599-608.
22. Mourey L, Samama JP, Delarue M, Petitou M, Choay J, Moras D. Crystal structure of cleaved bovine antithrombin III at 3.2A resolution. J Mol Biol 1993; 232: 223-241.
23. Schreuder HA, de Boer B, Dijkema R et al. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct Biol 1994; 1: 48-54.
24. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3A structure of dimeric antithrombin. Structure 1994; 2: 257-270.
25. Stein PE, Leslie AGW, Finch JT, Turnell WG, McLaughlin PJ, Carrell RW. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 1990; 347: 99-102.
26. Mottonen J, Strand A, Symersky J et al. Structural basis of latency in plasminogen activator inhibitor-I. Nature 1992; 355: 270-273.
27. Stein PE, Leslie AGW, Finch JT, Carrell RW. Crystal structure of uncleaved ovalbumin at 1.95A resolution. J Mol Biol 1991; 221: 941-959.
28. Wright HT, Qian HX, Huber R. Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin. Its relationship to the structure of cleaved alphal-proteinase inhibitor. J Mol Biol 1990; 213: 513-528.
29. Gettins P. Absence of large scale conformational change upon limited proteolysis of ovalbumin, the prototypic serpin. J Biol Chem 1989; 264: 3781-3785.
30. Stein P, Chothia C. Serpin tertiary structure transformation. J Mol Biol 1991; 221: 615-621.
31. 1-antitrypsin by a peptide sequentially similar to β-strand s4A. FEBS Letts 1990; 194: 51-56.
32. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991; 353: 576-578.
33. 14 region of the putative reactive bond loop of the inhibitor. J Biol Chem 1992; 267: 1976-1982.
34. Griffith MJ. Kinetics of heparin enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin. J Biol Chem 1982; 257: 7360-7365.
35. Griffith MJ. The heparin enhanced antithrombin III/thrombin reaction is saturable with respect to both thrombin and antithrombin III. J Biol Chem 1982; 257: 13899-13902.
36. Pomerantz MW, Owen WG. A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor, thrombin and heparin. Biochim Biophys Acta 1978; 535: 66-77.
37. Olson ST, Halvorson HR, Bjork I. Quantitative characterisation of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J Biol Chem 1991; 266: 6342-6352.
38. Olson ST, Bjork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J Biol Chem 1991; 266: 6353-6364.
39. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732.
40. Gettins P, Fan B, Crews B, Turko I, Olson S, Streusand V. Transmission of conformational change from the heparin binding site to the reactive center of antithrombin. Biochemistry 1993; 32: 8385-8389.
41. Dawes J, James K, Lane DA. The conformational change in antithrombin induced by heparin, probed with a monoclonal antibody against the 1C/4B region. Biochemistry 1994; 33: 4375-4383.
42. Hook M, Bjork I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: separation of high activity and low activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Letts 1976; 66: 90-93.
43. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Comm 1976; 69: 570-577.
44. Lindahl U, Backstrom G, Thunberg L, Leder IG. Evidence for a 3-O-sulfated D-glycosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 1980; 77: 6551-6555.
45. Casu B, Oreste P, Torri G. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III binding sequence. Biochem J 1981; 80: 599.
46. Thunberg L, Backstrom G, Lindahl U. Further characterisation of the antithrombin-binding sequence in heparin. Carbohydrate Res. 1982; 100: 393-410.
47. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.
48. Atha DH, Stephens AW, Rosenberg RD. Evaluation of critical groups required for binding of heparin to antithrombin. Proc Natl Acad Sci USA 1984; 81: 1030-1034.
49. Jordan RE, Beeler D, Rosenberg RD. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-2913.
50. Nordenman B, Danielsson A, Bjork I. The binding of low affinity and high affinity heparin to antithrombin. Fluorescence studies. Eur J Biochem 1978; 90: 1-6.
51. Blackburn MN, Sibley CC. The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue. J Biol Chem 1980; 255: 824 826.
52. Gettins P, Choay J, Crews BC, Zettlmeiss G. Role of tryptophan 49 in the heparin cofactor activity of human antithrombin III. J Biol Chem 1992; 267: 21946-53.
53. Liu CS, Chang JY. Probing the heparin binding domain of human antithrombin III with V8 protease. Eur J Biochem 1987; 167: 247-252.
54. Borg JY, Owen MC, Soria C, Soria J, Caen J, Carrell RW. Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser. J Clin Invest 1988; 81: 1292-1296.
55. Liu CS, Chang JY. The heparin binding site of human antithrombin III. Selective chemical modification at Lys 114, Lys 125 and Lys 287 impairs its heparin cofactor activity. J Biol Chem 1987; 262: 17356 17361.
56. Chang JY. Binding of heparin to human antithrombin III activates selective chemical modification at lysine 236. Lys107, Lys-125 and Lys-136 are situated within the heparin binding site of antithrombin III. J Biol Chem 1989; 264: 3111-3115.
57. Smith JW, Dey N, Knauer DJ. Heparin binding domain of antithrombin III: characterization using a synthetic peptide directed polyclonal antibody. Biochemistry 1990; 29: 8950-8957.
58. Fan B, Turko IV, Gettins PGW. Lysine-heparin interactions in antithrombin. Properties of K125M and K290M, K294M, K297M variants. Biochemistry 1994; 33: 14156-14161.
59. Turko IV, Fan B, Gettins PGW. Carbohydrate isoforms of antithrombin variant N135Q with different heparin affinities. FEBS Lett 1993; 335: 9-12.
60. Erdsal-Badju E, Lu A, Peng X et al. Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a β-like variant in baculovirus-infected insect cells. Biochem J 1995; 310: in press.
61. Lane DA, Olds RJ, Conard J et al. Pleiotropic effects of antithrombin strand IC substitution mutations. J Clin Invest 1992; 90: 2422-2433.
62. Mille B, Watton J, Barrowcliffe TW, Mani JC, Lane DA. Role of N and C terminal amino acids in antithrombin binding to pentasaccharide. J Biol Chem 1994; 269: 29435-29443.
63. Lane DA, Olds RJ, Thein SL. Antithrombin and its deficiency states. Blood Coag Fibrinol 1992; 3: 315-341.
64. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Eng J Med 1975; 292: 146-151.
65. Abildgaard U. Antithrombin and related inhibitors of coagulation. In: Poller L, ed. Recent Advances in Blood Coagulation, vol. 3. Edinburgh: Churchill Livingstone, 1981: 151-173.
66. Tait RC, Walker ID, Perry DJ et al. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemost 1991; 65: 839.
67. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87 (suppl 3B): 34S-38S.
68. Harper PL, Luddington RJ, Daly M et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991; 77(3): 360-364.
69. Tabernero MD, Tomas JF, Alberca I, Orfao A, Lopez Borrasca A, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36(4): 249-254.
70. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516.
71. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390.
72. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116:754-61.
73. Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. Surgery 1985; 97: 242-246.
74. Coller BS, Owen J, Jesty J et al. Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7(5): 456-462.
75. Johnson EJ, Prentice CR, Parapia LA. Premature arterial disease associated with familial antithrombin III deficiency. Thromb Haemost 1990; 63(1): 13 15.
76. Chowdhury V, Lane DA, Auberger K et al. Homozygous antithrombin deficiency: report of two new cases (99Leuto Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 166-329.
77. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094.
78. Girolami A, Lazzaro AR, Simioni P. The relationship between defective heparin cofactor activities and thrombotic phenomena in ATIII abnormalities. Thromb Haemost 1988; 59: 121.
79. Olds RJ, Lane DA, Caso R et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin super family. Blood 1992; 79: 1206-1212.
80. Rosendaal FR, Heijboer H, Briet E et al. Mortality in hereditary antithrombin III deficiency 1830-1989. Lancet 1991; 337: 260-262.
81. van Boven HH, Olds RJ, Thein SL et al. Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. Blood 1994; 84:4209-4213.
82. Dahlback B, Carlsson M, Svensson PI Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
83. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
84. van Boven HH, Reitsma PH, Rosendaal FR et al. Factor V Leiden in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-421.
85. Sas G, Blasko G, Banhegyi D, Jako J, Palos LA. Abnormal antithrombin III (Antithrombin III 'Budapest') as a cause of a familial thrombophilia. Thromb Diathes Haemorrh 1974; 32: 105-115.
86. Hultin MB, McKay J, Abildgaard U. Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family with a review of hereditary antithrombin variants. Thromb Haemost 1988; 59: 468-473.
87. Lane DA, Ireland H, Olds RJ, Thein SL, Perry DJ, Aiach M. Antithrombin III: a database of mutations. Thromb Haemost 1991; 66: 657-661.
88. Lane DA, Olds RJ, Boisclair M et al. Antithrombin III mutation database: first update. Thromb Haemost 1993; 70: 361-369.
89. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrhag 1965; 13: 516-530.
90. Winter JH, Bennett B, Watt JL et al. Confirmation of linkage between antithrombin III and Duffy blood group and assignment of AT3 to 1q22-25. Annal Hum Genet 1982; 26: 29-34.
91. Magenis RE, Donlon T, Parks M, Rivas ML, Lovrien EW Linkage relationships of dominant antithrombin III deficiency and the heterochromatic region of chromosome 1. Cytogenet Cell Genet 1978; 22: 327-329.
92. Lovrien EW, Magenis RE, Rivas ML, Goodnight S, Moreland R, Rowe S. Linkage study of antithrombin III. Cytogenet Cell Genet 1978; 22: 319-323.
93. Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet 1985; 39: 67-69.
94. Bock SC, Harris JF, Schwartz CE, Ward JH, Hersgold EJ, Skolnick MH. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet 1985; 37: 32-41.
95. Sacks SH, Old JM, Reeders ST et al. Evidence linking familial thrombosis with a defective antithrombin III gene in two British kindreds. J Med Genet 1988; 25: 20-24.
96. Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 27: 6171-6178.
97. Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry 1993; 32: 4216-4224.
98. Olds RJ, Lane DA, Chowdhury V et al. (ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations. Hum Mutat 1994; 4: 31-41.
99. Prochownik EV. Relationship between an enhancer element in the human antithrombin III gene and an immunoglobulin light-chain gene enhancer. Nature 1985; 316(6031): 845 848.
100. Ochoa A, Brunei F, Mendelzon D, Cohen GN, Zakin MM. Different liver nuclear proteins binds to similar DNA sequences in the 5′ flanking regions of three hepatic genes. Nucleic Acids Res 1989; 17: 119-133.
101. Nieseen R, Rezaee F, de Vijlder J, Sturk A. Human antithrombin III gene expression is probably regulated by a hormone receptor response element. Thromb Haemost 1995; 73: 1343 (abstract 1342).
102. Rosenberg J, Bergtrom G, Amrani D. Identification of FXP1 and LF1 regulatory sites in the 5′ upstream region of the human antithrombin gene. Thromb Haemost 1995; 73: 1249 (abstract 1335).
103. Prochownik EV, Orkin SH. In vivo transcription of a human antithrombin III 'minigene'. J Biol Chem 1984; 259: 15386-15392.
104. Prochownik EV, Smith MJ, Markham A. Two regions downstream of AATAAA in the human antithrombin III gene are important for cleavage-polyadenylation. J Biol Chem 1987; 262(19): 9004-9010.
105. Prochownik EV, Antonarakis S, Bauer KA, Rosenberg RD, Fearon ER, Orkin SH. Molecular heterogeneity of inherited antithrombin III deficiency. N Eng J Med 1983; 308: 1549-1552.
106. Bock SC, Radziejewska E. A Nhe 1 RFLP in the human antithrombin III gene (1q23-25) (AT3). Nucl Acids Res 1991; 19:2519.
107. Daly ME, Perry DJ. Ddel polymorphism in intron 5 of the ATIII gene. Nucl Acids Res 1990; 18: 5583.
108. Bock SC, Levitan DJ. Characterisation of an unusual DNA length polymorphism 5′ to the human antithrombin III gene. Nucl Acids Res 1983; 11: 8569-8582.
109. Olds RJ, Lane DA, Ireland H et al. A common point mutation producing type 1a antithrombin III deficiency: AT129CGA to TGA (Arg to Stop). Thromb Res 1991; 64: 621 625.
110. Olds RJ, Lane DA, Beresford CH, Abildgard U, Hughes PM, Thein SL. A recurrent deletion in the antithrombin gene, AT106-108(-6bp), identified by DNA heteroduplex detection. Genomics 1993; 16: 298-299.
111. Olds RJ, Lane DA, Chowdhury V et al. Major rearrangements within the antithrombin locus: an unusual cause for inherited antithrombin deficiency. Br J Haematol 1992; ISH 24th Congress Abstracts: 40.
112. Fernandez-Rachubinski F, Rachubinski R, Blajchman M. Partial deletion of an antithrombin III allele in a kindred with type I deficiency. Blood 1992; 80: 1476-1485.
113. Erdjument H, Lane DA, Ireland H et al. Formation of a covalent disulphide-linked antithrombin-albumin complex by an antithrombin variant, antithrombin Northwick Park. J Biol Chem 1987; 262: 13381 -13384.
114. Erdjument H, Lane DA, Panico M, DiMarzo V, Morris HR. Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow. J Biol Chem 1988; 263: 5589-5593.
115. Lane DA, Erdjument H, Thompson E et al. A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin Pescara, Arg 393 to Pro, caused by a CGT to CCT mutation. J Biol Chem 1989; 264: 10200-10204.
116. Erdjument H, Lane DA, Ireland H et al. Antithrombin Milano, single amino acid substitution at the reactive site. Thromb Haemost 1988; 60: 471-475.
117. Erdjument H, Lane DA, Panico M et al. Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thromb Res 1989; 54: 613-619.
118. Lane DA, Erdjument H, Flynn A et al. Antithrombin Sheffield: amino acid substitution at the reactive site (Arg 393 to His) causing thrombosis. Br J Haematol 1989; 71: 91-96.
119. Ireland H, Lane DA, Thompson E et al. Antithrombin Frankfurt I: arginine to cysteine substitution at the reactive site and formation of a variant antithrombin-albumin covalent complex. Thromb Haemostas 1991; 65:913.
120. Blajchman MA, Fernandez-Rachubinski F, Sheffield WP, Austin RC, Schulman S. Antithrombin III Stockholm: a codon 392 (Gly to Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood 1992; 79: 1428-1434.
121. Lane DA, Flynn A, Ireland H et al. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin. Br J Haematol 1987; 65: 451-456.
122. Lane DA, Lowe GDO, Flynn A, Thompson E, Ireland H, Erdjument H. Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis. Br J Haematol 1987; 66: 523-527.
123. Watton J, Longstaff C, Lane DA, Barrowcliffe TW. Heparin binding affinity of normal and genetically modified antithrombin III measured using a monoclonal antibody to the heparin binding site of antithrombin III. Biochemistry 1993; 32: 7286-7293.
124. Stephens AW, Thalley BS, Hirs CHW. Antithrombin-III Denver, a reactive site variant. J Biol Chem 1987; 262: 1044-1048.
125. Stephens AW, Siddiqui A, Hirs CH. Expression of functionally active human antithrombin III. Proc Natl Acad Sci U S A 1987; 84: 3886-3890.
126. Olson ST, Sheffer R, Stephens AW, Hirs CHW. Molecular basis of the reduced activity of antithrombin-Denver with thrombin and factor Xa. Role of the P 1 residue. Thromb Haemostas 1991; 65: 670.
127. Devraj-Kizuk R, Chui DHK, Prochownik EV, Carter CJ, Ofosu FA, Blajchman MA. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood 1988; 72: 1518-1523.
128. Mohlo-Sabatier P, Aiach M, Gaillard I et al. Molecular characterisation of antithrombin III (AT III) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala384 Pro mutation. J Clin Invest 1989; 84: 1236-1241.
129. Caso R, Lane DA, Olds RJ et al. Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate. Brit J Haematol 1990; 97: 87-92.
130. Ireland H, Lane DA, Thompson E et al. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin. Br J Haematol 1991; 79: 70-74.
131. Rijken DC, Groeneveld E, Kluft C, Nieuwenhuis HK. Alpha2-antiplasmin Enschede is not an inhibitor, but a substrate of plasmin. Biochem J 1988; 255: 609-615.
132. Skriver K, Wikoff WR, Patston PA et al. Substrate properties of C1 inhibitor Ma (A434E). Genetic and structural evidence suggesting that the 'P12-region' contains critical determinants of serpin inhibitor/substrate status. J Biol Chem 1991; 266: 9216-9221.
133. Davis AE, Aulak K, Parad RB et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics 1992; 1: 354-358.
134. Bruce D, Perry DJ, Borg J-Y, Carrell RW, Wardell MR. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen VI (187 Asn to Asp). J Clin Invest 1994; 94: 2265-2274.
135. Brennan SO, Borg JY, George PM et al. New carbohydrate site in mutant antithrombin (7 Ile-Asn) with decreased heparin affinity. FEBS Letts. 1988; 237: 118-122.
136. Borg JY, Brennan SO, Carrell RW, George P, Perry DJ, Shaw J. Antithrombin Rouen-IV 24 Arg◆Cys. The amino-terminal contribution to heparin binding. FEBS Letts 1990; 266: 163-166.
137. Olds RJ, Lane DA, Boisclair M, Sas G, Bock SC, Thein SL. Antithrombin Budapest 3: an antithrombin variant with reduced heparin affinity resulting from the substitution L99F. FEBS Letts 1992; 300: 241-246.
138. Okajima K, Abe H, Maeda S et al. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Blood 1993; 81: 1300-1305.
139. Chowdury V, Mille B, Olds RJ et al. Antithrombin Southport (99Leu to Val) and Vienna (118Gln to Pro): two novel antithrombin variants which have abnormal heparin binding. Br J Haematol 1994; 89: 602-609.
140. Gandrille S, Aiach M, Lane DA et al. Important role of arginine 129 in heparin-binding site of antithrombin III. J Biol Chem 1990; 265: 18997-19001.
141. Church FC, Meade JB, Treanor RE, Whinna HC. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III and thrombin. J Biol Chem 1989; 264: 3618-3623.
142. Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alphal-proteinase inhibitor, alphal-antichymotrypsin, antithrombin III, alpha2-antiplasmin, and ovalbumin. Biochemistry 1991; 30: 1723-1730.
143. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990; 87: 3753-3757.
144. Perlmutter DH, Joslin G, Nelson P, Schasteen C, Adams P, Fallon RJ. Endocytosis ans degradation of alphal-antitrypsin-protease complexes is mediated by the serpin-enzme complex (SEC) receptor. J Biol Chem 1990; 265: 16713-16716.
145. Daly ME, Perry DJ, Harper PL, Carrell RW. The molecular basis of quantitative antithrombin deficiency in 8 unrelated families. Br J Haematol 1992; 80: 15.
146. Daly ME, Perry DJ, Harper PL, Daly HM, Roques AWW, Carrell RW. Insertions/deletions in the antithrombin gene: 3 mutations associated with non-expression. Thromb Haemost 1992; 67: 521-525.
147. Chowdhury V, Olds RJ, Lane DA et al. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol 1993; 84: 656-661.
148. Olds RJ, Lane DA, Ireland H et al. Novel point mutations leading to type 1 antithrombin deficiency and thrombosis. Br J Haematol 1991; 78:409-413.
149. Olds RJ, Lane DA, Finazzi. G, Barbui T, Thein SL. A frameshift mutation leading to type 1 antithrombin deficiency and thrombosis. Blood 1990; 76: 2182-2186.
150. Gandrille S, Vidaud D, Emmerich J et al. Molecular basis for hereditary antithrombin III quantitative deficiencies: a stop codon on exon IIIa and a frameshift in exon VI. Br J Haematol 1991; 78: 414-420.
151. Tomonori A, Iwahana H, Yoshimoto K, Shigekiyo T, Saito S, Itakura M. Two new nonsense mutations in type Ia antithrombin III deficiency at Leu 140 and Arg 197. Thromb Haemostas 1992; 68: 455-459.
152. Berg L-P, Grundy CB, Thomas F et al. De novo splice site mutation in the antithrombin III (AT3) gene causing recurrent venous thrombosis: demonstration of exon skipping by ectopic transcript analysis. Genomics 1992; 13: 1359-1361.
153. Vidaud D, Emmerich J, Sirieix ME, Sie P, Alhenc-Gelas M, Aiach M. Molecular basis for antithrombin III type I deficiency: 3 novel mutations located in exon IV. Blood 1991; 78: 2305-2309.
154. Grundy CB, Thomas F, Millar DS et al. Recurrent deletion in the human antithrombin III gene. Blood 1991; 78: 1027-1032.
155. Grundy CB, Holding S, Millar D S, Kakkar VV, Cooper DN. A novel missense mutation in the antithrombin III gene (Ser 349 to Pro) causing recurrent venous thrombosis. Human Genet 1992; 88: 707-708.
156. Vidaud D, Gandrille S, Emmerich J et al. Identification of 6 novel mutations responsible for type I AT III deficiencies. Thromb Haemostas 1991; 65: 762.
157. White D, Abraham G, Carter C, Kakkar W, Cooper DN. A novel missense mutation in the antithrombin III gene (Ala 387 to Val) causing recurrent venous thrombosis. Human Genet 1992; 90: 472-473.
158. Miller DS, Lopez A, White D et al. Screening for mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis by single strand conformation polymorphism analysis. Human Mutation 1992; 2: 324-326.
159. Vidaud D, Sireix ME, Ahlenc-Gelas M et al. A double heterozygosity in 2 brothers with antithrombin (ATIII) deficiency due to the association of an Arg 47 to His mutation with a 9 base pair (bp) deletion in exon VI. Thromb Haemost 1991; 65: 838.
160. Bock SC, Prochownik EV. Molecular genetic survey of 16 kindreds with hereditary antithrombin III deficiency. Blood 1987; 70: 1273-1278.
161. Perry DJ, Daly M, Harper PL et al. Antithrombin Cambridge II, 384 Ala to Ser. Further evidence of the role of the reactive centre loop in the inhibitory function of the serpin. FEBS Letts 1991; 285: 248 250.
162. Chang JY, Tran TH. Antithrombin III Basel: identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem 1986; 261: 1174-1176.
163. Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of Arginine 47 by Cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci USA 1984; 81: 289-293.
164. Owen MC, Borg JY, Soria C, Soria J, Caen J, Carrell RW Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His. Blood 1987; 69: 1275-1279.
165. Bock SC. Identification of a threonine for alanine substitution at residue 404 of antithrombin III Oslo suggests integrity of the 404-407 region is important for maintaining normal plasma inhibitor levels. Thromb Haemost 1989; 62:494 (abstract).
166. Nakagawa M, Tanaka S, Tsuji H, Takada O, Ono T. Congenital antithrombin deficiency (ATIII Kyoto): identification of a point mutation altering arginine-406 to methionine behind the reactive site. Thromb Res 1991; 64: 101-108.
167. Bjork I, Nordling K, Olson ST. Immunologic evidence for the insertion of the reactive bond loop of antithrombin into the sheet of the inhibitor during trapping of the target proteinases. J Biol Chem 1993; 32: 6501-6505.